Search

Your search keyword '"Miller, Timothy M."' showing total 622 results

Search Constraints

Start Over You searched for: Author "Miller, Timothy M." Remove constraint Author: "Miller, Timothy M."
622 results on '"Miller, Timothy M."'

Search Results

1. The expanding application of antisense oligonucleotides to neurodegenerative diseases

2. Characterization of Low-noise Backshort-Under-Grid Kilopixel Transition Edge Sensor Arrays for PIPER

3. NOS1AP is a novel molecular target and critical factor in TDP-43 pathology

4. Effect of sodium phenylbutyrate/taurursodiol on tracheostomy/ventilation-free survival and hospitalisation in amyotrophic lateral sclerosis: long-term results from the CENTAUR trial

8. TSC1 loss increases risk for tauopathy by inducing tau acetylation and preventing tau clearance via chaperone-mediated autophagy

9. An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients

10. Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taurursodiol in amyotrophic lateral sclerosis

12. Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis

13. SOFIA - HIRMES: Looking forward to the HIgh-Resolution Mid-infrarEd Spectrometer

18. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.

19. An integrated multi-omic analysis of iPSC-derived motor neurons from C9ORF72 ALS patients

21. The Primordial Inflation Polarization Explorer (PIPER)

22. Phosphorylated neurofilament heavy chain: A biomarker of survival for C9ORF72‐associated amyotrophic lateral sclerosis

23. Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis

24. Defining SOD1 ALS natural history to guide therapeutic clinical trial design

25. Body mass index is lower in asymptomatic C9orf72 expansion carriers but not in SOD1 pathogenic variant carriers compared to gene negatives.

29. The Primordial Inflation Polarization Explorer (PIPER)

30. The GISMO 2-millimeter Deep Field in GOODS-N

31. Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies

33. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene

34. Tau Kinetics in Neurons and the Human Central Nervous System

35. SILK studies — capturing the turnover of proteins linked to neurodegenerative diseases

37. COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success

38. TREM2 inhibition triggers antitumor cell activity of myeloid cells in glioblastoma

41. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS

43. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models

45. Protein kinetics of superoxide dismutase‐1 in familial and sporadic amyotrophic lateral sclerosis

46. Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS

47. Courage-als: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success

48. Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers

50. A dual MTOR/NAD+ acting gerotherapy

Catalog

Books, media, physical & digital resources